“…Furthermore, costunolide potentiated 1,25-(OH)2D3-induced differentiation in HL-60 promyelocytic leukemia cells (Choi et al, 2002b;Kim et al, 2008;Kim et al, 2002), via the interference with NF-κB activation. Further studies demonstrate that costunolide has antitumor potential by inhibiting proliferation, inducing apoptosis and reducing invasion and metastasis of a wide variety of tumor cells, including breast cancer cells (Bocca et al, 2004;Choi et al, 2005;Choi et al, 2011), hepatocellular carcinoma cells (Chen et al, 1995;Liu et al, 2011a;Sun et al, 2003), prostate cancer cells (Hsu et al, 2011), leukemia cells (Choi et al, 2002a;Choi and Lee, 2009;Choi et al, 2002b;Hibasami et al, 2003;Kanno et al, 2008;Kim et al, 2008;Kim et al, 2002;Kim et al, 2011b;Komiya et al, 2004;Lee et al, 2001;Song et al, 2001;Srivastava et al, 2006), gastric cancer cells (Ko et al, 2005;Rasul et al, 2011), colon cancer cells (Kawamori et al, 1995;Mori et al, 1994), melanoma cells (Chen et al, 2007;Park et al, 2001b), cervical cancer cells (Sun et al, 2003), KB and P388 tumor cell (Mondranondra et al, 1990), and platinum-resistant human ovarian cancer cells . It was also reported that costunolide inhibited angiogenic response by blocking the angiogenic factor signaling pathway (Jeong et al, 2002) and microtubule-interactting activity of costunolide (Bocca et al, 2004).…”